Company: NCNA
Filing Date: 2025-06-27
Form Type: 424B5
Source: 0001193125-25-151464
Chunk: 13

Company: NuCana plc
Filing Date: 2025-06-27
Form: 424B5
Chunk 13
---
-Ksfrom time to time, as filed with the SEC and which are incorporated herein by reference. The information contained in this document is believed to be current as of the date of this document. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. S-9

In light of these assumptions, risks and uncertainties, the results and events discussed in
the forward-looking statements contained in this prospectus supplement or in any document incorporated herein by reference might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of
the date of this prospectus supplement or the date of the document incorporated by reference in this prospectus supplement. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained
or referred to in this section.

S-10

USE OF PROCEEDS

We may issue and sell our ADSs having aggregate sale proceeds of up to $100.0 million from time to time. Because there is no minimum
offering amount required to be sold in connection with this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We estimate that the net proceeds from our issuance and sale of
$100.0 million ADSs in this offering will be approximately $96.6 million, after deducting Placement Agent fees and estimated offering expenses payable by us. We intend to use any net proceeds from the sale of securities under this
prospectus supplement to fund activities relating to the advancement of our drug discovery and development programs, and for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments,
acquisitions, should we choose to pursue any, and collaborations. The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other development efforts and other factors
described under “Risk Factors” in this prospectus supplement and the documents incorporated by reference herein, as well as the amount of cash used in our operations. As a result, our management will have broad discretion to allocate the
net proceeds, if any, we receive in